tetano
Editor, Senior Moderator
Microbiol Spectr
. 2023 Jun 13;e0066023.
doi: 10.1128/spectrum.00660-23. Online ahead of print. Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay
Mako Toyoda[SUP] 1 2 [/SUP], Toong Seng Tan[SUP] 1 [/SUP], Chihiro Motozono[SUP] 1 [/SUP], Godfrey Barabona[SUP] 1 [/SUP], Akiko Yonekawa[SUP] 3 [/SUP], Nobuyuki Shimono[SUP] 3 [/SUP], Rumi Minami[SUP] 4 [/SUP], Yoji Nagasaki[SUP] 5 [/SUP], Yusuke Miyashita[SUP] 6 7 [/SUP], Hiroyuki Oshiumi[SUP] 6 [/SUP], Kimitoshi Nakamura[SUP] 7 [/SUP], Shuzo Matsushita[SUP] 8 [/SUP], Takeo Kuwata[SUP] 8 [/SUP], Takamasa Ueno[SUP] 1 [/SUP]
Affiliations
Neutralizing potency of humoral immune responses induced by prior infection or vaccination is vital for protecting of individuals and population against severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). However, the emergence of viral variants that can evade neutralization by vaccine- or infection-induced immunity is a significant public health threat and requires continuous monitoring. Here, we have developed a novel scalable chemiluminescence-based assay for assessing SARS-CoV-2-induced cytopathic effect to quantify the neutralizing activity of antisera. The assay leverages the correlation between host cell viability and ATP levels in culture to measure the cytopathic effect on target cells induced by clinically isolated, replication-competent, authentic SARS-CoV-2. With this assay, we demonstrate that the recently arisen Omicron subvariants BQ.1.1 and XBB.1 display a significant decrease in sensitivity to neutralization by antibodies elicited from breakthrough infections with Omicron BA.5 and from receipt of three doses of mRNA vaccines. Thus, this scalable neutralizing assay provides a useful platform to assess the potency of acquired humoral immunity against newly emerging SARS-CoV-2 variants. IMPORTANCE The ongoing global pandemic of SARS-CoV-2 has emphasized the importance of neutralizing immunity in protecting individuals and populations against severe respiratory illness. In light of the emergence of viral variants with the potential to evade immunity, continuous monitoring is imperative. A virus plaque reduction neutralization test (PRNT) is a "gold standard" assay for analyzing neutralizing activity for authentic viruses that form plaques, like influenza virus, dengue virus, and SARS-CoV-2. However, this method is labor intensive and is not efficient for performing large-scale neutralization assays on patient specimens. The assay system established in this study allows for the detection of a patient's neutralizing activity by simply adding an ATP detection reagent, providing a simple evaluation system for neutralizing activity of antisera as an alternative to the plaque reduction method. Our extended analysis of the Omicron subvariants highlights their increasing capability to evade neutralization by both vaccine- and infection-induced humoral immunity.
Keywords: Omicron subvariants; SARS-CoV-2; cytopathic effect; neutralizing assay.
. 2023 Jun 13;e0066023.
doi: 10.1128/spectrum.00660-23. Online ahead of print. Evaluation of Neutralizing Activity against Omicron Subvariants in BA.5 Breakthrough Infection and Three-Dose Vaccination Using a Novel Chemiluminescence-Based, Virus-Mediated Cytopathic Assay
Mako Toyoda[SUP] 1 2 [/SUP], Toong Seng Tan[SUP] 1 [/SUP], Chihiro Motozono[SUP] 1 [/SUP], Godfrey Barabona[SUP] 1 [/SUP], Akiko Yonekawa[SUP] 3 [/SUP], Nobuyuki Shimono[SUP] 3 [/SUP], Rumi Minami[SUP] 4 [/SUP], Yoji Nagasaki[SUP] 5 [/SUP], Yusuke Miyashita[SUP] 6 7 [/SUP], Hiroyuki Oshiumi[SUP] 6 [/SUP], Kimitoshi Nakamura[SUP] 7 [/SUP], Shuzo Matsushita[SUP] 8 [/SUP], Takeo Kuwata[SUP] 8 [/SUP], Takamasa Ueno[SUP] 1 [/SUP]
Affiliations
- PMID: 37310218
- DOI: 10.1128/spectrum.00660-23
Neutralizing potency of humoral immune responses induced by prior infection or vaccination is vital for protecting of individuals and population against severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). However, the emergence of viral variants that can evade neutralization by vaccine- or infection-induced immunity is a significant public health threat and requires continuous monitoring. Here, we have developed a novel scalable chemiluminescence-based assay for assessing SARS-CoV-2-induced cytopathic effect to quantify the neutralizing activity of antisera. The assay leverages the correlation between host cell viability and ATP levels in culture to measure the cytopathic effect on target cells induced by clinically isolated, replication-competent, authentic SARS-CoV-2. With this assay, we demonstrate that the recently arisen Omicron subvariants BQ.1.1 and XBB.1 display a significant decrease in sensitivity to neutralization by antibodies elicited from breakthrough infections with Omicron BA.5 and from receipt of three doses of mRNA vaccines. Thus, this scalable neutralizing assay provides a useful platform to assess the potency of acquired humoral immunity against newly emerging SARS-CoV-2 variants. IMPORTANCE The ongoing global pandemic of SARS-CoV-2 has emphasized the importance of neutralizing immunity in protecting individuals and populations against severe respiratory illness. In light of the emergence of viral variants with the potential to evade immunity, continuous monitoring is imperative. A virus plaque reduction neutralization test (PRNT) is a "gold standard" assay for analyzing neutralizing activity for authentic viruses that form plaques, like influenza virus, dengue virus, and SARS-CoV-2. However, this method is labor intensive and is not efficient for performing large-scale neutralization assays on patient specimens. The assay system established in this study allows for the detection of a patient's neutralizing activity by simply adding an ATP detection reagent, providing a simple evaluation system for neutralizing activity of antisera as an alternative to the plaque reduction method. Our extended analysis of the Omicron subvariants highlights their increasing capability to evade neutralization by both vaccine- and infection-induced humoral immunity.
Keywords: Omicron subvariants; SARS-CoV-2; cytopathic effect; neutralizing assay.